Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

12.29USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$12.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
147,041
52-wk High
$16.80
52-wk Low
$7.20

OMER.OQ

Chart for OMER.OQ

About

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's marketed drug product, Omidria (phenylephrine... (more)

Overall

Beta: 3.34
Market Cap(Mil.): $561.77
Shares Outstanding(Mil.): 42.92
Dividend: --
Yield (%): --

Financials

  OMER.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.72 -- --
ROI: -176.50 -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Omeros Q3 loss per share $0.34

* Omeros Corporation reports third quarter 2016 financial results

Nov 09 2016

BRIEF-Omeros files orphan drug application for OMS721 in Immunoglobulin A nephropathy

* Files orphan drug application for OMS721 in Immunoglobulin A nephropathy

Nov 03 2016

BRIEF-Omeros announces positive data from mid-stage clinical trial evaluating PPAR-Gamma agonist in heroin users

* Trial demonstrated that compound statistically significantly reduced drug craving and measures of anxiety in heroin users maintained on sublingual buprenorphine/naloxone

Nov 02 2016

BRIEF-Omeros announces $125 million new credit facility

* New credit facility consists of an $80 million term loan to be drawn by company within ten business days

Oct 27 2016

BRIEF-Omeros Corp announces positive data from OMS721 phase 2 trial

* Omeros announces positive data from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy

Oct 20 2016

BRIEF-Omeros announces positive data from OMS721 phase 2 clinical trial in renal diseases

* Omeros announces positive data from OMS721 Phase 2 clinical trial in renal diseases

Oct 17 2016

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

Aug 11 2016

BRIEF-Omeros announces public offering of common stock

* Intends to use net proceeds for funding research and development expenses for its clinical OMS721 program and clinical trials

Aug 10 2016

BRIEF-Omeros confirms late-stage development plan for OMS721 with EMA

* Omeros corporation confirms oms721 phase 3 development plan with european medicines agency

Jul 28 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $111.30 --
Novartis AG (NOVN.S) CHF69.30 -0.95
Pfizer Inc. (PFE.N) $32.14 --
Roche Holding Ltd. (ROG.S) CHF223.20 -3.50
Roche Holding Ltd. (RO.S) CHF226.00 -4.10
Merck & Co., Inc. (MRK.N) $61.19 --
Bayer AG (BAYGn.DE) €86.99 -1.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.94 -1.17
Eli Lilly and Co (LLY.N) $67.12 --

Earnings vs. Estimates